Synthesis and antileprosy activity of some dialkyldithiocarbamates

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1134-1138

  Makarov, Vadim ^a   Riabova, Olga B ^a   Yuschenko, Anatoly ^b   Urlyapova, Nailya ^b   Daudova, Adilya ^b   Zipfel, Peter F ^c   Möllmann, Ute ^c  

^a National Research Centre of Antibiotics   (Russian Federation)

^b Leprosy Research Institute   (Russian Federation)

^c HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Antileprosy agents; Dithiocarbamates; Leprosy; Mouse footpad model; Nitropyridines

Indexed keywords

3 CYANO 2 DIETHYLDITHIOCARBAMOYL 5 NITROPYRIDINE; 3 CYANO 2 HEXAMETHYLENDITHIOCARBAMOYL 5 NITROPYRIDINE; 3 CYANO 5 NITRO 2 PENTAMETHYLENDITHIOCARBAMOYLPYRIDINE; 3 CYANO 5 NITRO 2 TETRAMETHYLENDITHIOCARBAMOYLPYRIDINE; 3,5 DINITRO 2 TETRAHYDROMETHYLENDITHIOCARBAMOYLBENZAMIDE; 6 METHOXY(DIMETHYLAMINO) 5 NITRO 4 TETRAHYDROMETHYLENDITHIOCARBAMOYLPYRIMIDINE DERIVATIVE; DAPSONE; DITHIOCARBAMIC ACID DERIVATIVE; LEPROSTATIC AGENT; UNCLASSIFIED DRUG; THIOCARBAMIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FOOT PAD; IN VITRO STUDY; IN VIVO STUDY; LEPROSY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM AURUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM VACCAE; NONHUMAN; TOXICITY; ANIMAL; BACTERIAL COUNT; CBA MOUSE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOBACTERIUM; SYNTHESIS;

ANIMALS; COLONY COUNT, MICROBIAL; DAPSONE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MICE; MICE, INBRED CBA; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM; MYCOBACTERIUM LEPRAE; THIOCARBAMATES;

EID: 33749163237     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl095     Document Type: Article

References (19)

1. Faget GH, Pogge RC, Johansen FA et al. La prominoterapia de la lepra. Estudios en Progresso. Int J Lepr 1943; 11: 52-63.
2. Lowe J. Treatment of leprosy with diamino-diphenyl sulphone by mouth. Lancet 1950; i: 145-50.
3. Jacobson RR, Hastings RC. Rifampin-resistant leprosy. Lancet 1976; ii: 1304-5.
4. Yawalkar SJ, Vischer W. Lamprene (clofazimine) in leprosy. Lepr Rev 1979; 50: 135-44.
5. Anon. Clofazimine: New products. Major antileprous drug. Prescrire Int 1999; 40: 44-6.
6. Ji B, Sow S, Perani E et al, Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother 1998; 42: 1115-20.
7. Bakker MI, Hatta M, Kwenang A et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg 2005: 72: 443-8.
8. You EY, Kang TJ, Kim SK. Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J Infect 2005; 50: 6-11.
9. Zhang L, Namisato M, Matsuoka M. A mutation at codon 516 in the rpoB gene of Mycobacterium leprae confers resistance to rifampin. Int J Lepr Other Mycobact Dis 2004; 72: 468-72.
10. Makarov V, Möllmann U. Dithiocarbamate derivatives and their use as antibacterial agents. PCT Int. Appl. WO 03/042186.
11. Makarov V, Möllmann U, Ryabova O et al. 2-Dithiocarbamatopyridin-derivate, Verfahren zu ihrer Herstellung und ihre Verwendung. German Appl. 102005031353, 1; Priority 01.07.2005.
12. Fanta PE, Stein RA. The condensation of sodium nitromalonaldehyde with cyanoacetamide. J Amer Chem Soc 1955; 77: 1045-6.
13. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA, USA, 1997.
14. Shepard CC. The experimental disease that follows the infection of human leprosy bacilli info footpads of mice. J Exp Med 1960; 112: 445-54.
15. Anon. WHO expert committee on leprosy. World Health Organ Tech Rep Ser 1977; 607: 7-48.
16. Shepard CC, McRae DH. A method of counting acid-fast bacteria. Int J Lepr Other Mycobact Dis 1968; 36: 78-82.
17. Winn M, Zydowsky TM, Altenbach RJ. 2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists. J Med Chem 1993: 36: 2676-88.
18. Gidoh M, Tsutsumi S. The inhibitory effects by combined doses of DDS and several immunostimulants on the growth of leprosy bacilli inoculated into footpads of hybrid nude mice, Jcl:AF-nu. Nippon Rai Gakkai Zasshi 1989; 58: 241-9.
19. Gelber RH. Another view of the therapy of leprosy. Antimicrob Agents Chemother 1998; 42: 3334-6.